Alan T. Henley

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Florence I. Raynaud, Suzanne A. Eccles, Paul A. Clarke et al. · Cancer Research · 2007 · 352 citations · Full text

Medicine, Oncology, Pharmacology +10

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

Diana Carvalho, Kathryn R. Taylor, Nagore G. Olaciregui et al. · Communications Biology · 2019 · 122 citations · Full text

Medicine, Oncology, Pharmacology +7

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter et al. · Molecular Cancer Therapeutics · 2010 · 86 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of 4-Amino-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)

Tatiana McHardy, John Caldwell, Kwai-Ming J. Cheung et al. · Journal of Medicinal Chemistry · 2010 · 83 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15